Like I said, address the cause of the demand increase and you'll address both the price and provide and improvement to peoples' quality of life.
There is a scaling issue but my point stands, that demand & its growth are stable and predictable. These are companies with at least 5 & 10 year plans, so they’re able to match production to demand long term.
And my point still stands that preventative measures will have both a positive impact on peoples' health and on the demand for insulin.
Price gouging is definitely a problem that has to be addressed, but it's not the only one - yet seems to be what everyone focuses on first while glossing over the terrible lifestyles/habits of the population.
Just because there's more than one obvious problem doesn't mean that you can ignore the others.
More to the point, this isn't just about a single disease or drug, the same story applies to a lot of medication, including those that have zero lifestyle causes.
EpiPens are another example mentioned in the article. In the US if your child is born with a deadly allergy you have to carry around very expensive EpiPens that can cost hundreds of dollars due to co-pay and whatever. In Europe these will cost you directly less than $10 and even to the state will cost a lot less than it does to many US patients. One of the company's responses to hiking the price from $50 to $600 for profit reasons was to introduce a cheaper generic version, which as this article points out, is BS.